RT info:eu-repo/semantics/article
T1 Un nuevo tratamiento para las epístaxis de la enfermedad de Rendu-Osler-Weber ó telangiectasia hemorrágica hereditaria (HHT).
A1 Morais Pérez, Darío
A2 Ediciones Universidad de Valladolid
AB Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber syndrome is an autosomal dominant vascular rare disease whose clinical manifestations are mucocutaneous and gastrointestinal telangiectases and localized arteriovenous malformations in lung, brain and liver. Epistaxis, due to the telangiectases on the nasal mucosa, is the most frequent clinical manifestation of this syndrome leading in many cases to severe impairment of the quality of life in the patients.Several treatments have been used to reduce epistaxis, but none has been completely effective. The polydocanol (Aethoxysklerol ®) in submucosa or subpericondric injection was first presented for us in 2000, with very good results.After more than fifteen years using the polydocanol in submucosa injection in almost one hundred patients and over 500 injections, we have confirmed that over 95 % of these patients improved their nose bleeds without important side effects.
SN 0210-6523
YR 2013
FD 2013
LK http://uvadoc.uva.es/handle/10324/23841
UL http://uvadoc.uva.es/handle/10324/23841
LA spa
NO Anales de la Real Academia de Medicina y Cirugía de Valladolid, 2013, N.50, pags.245-255
DS UVaDOC
RD 25-abr-2024